Sonrotoclax, a BCL2 inhibitor, received FDA breakthrough therapy designation for relapsed or refractory mantle cell lymphoma, indicating its potential to transform patient outcomes. The drug is ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417 ...
Please provide your email address to receive an email when new articles are posted on . Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in ...
Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne to participate in Project Orbis ...
Paul Madley, 66, said he doesn't know 'where he would be' without a 'life-saving' cancer treatment, which has now been removed from the NHS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results